“Assessing the Benefits of Rosiglitazone in Women With Polycystic Ovary Syndrome through Its Effects on Insulin-Like Growth Factor 1, Insulin-Like Growth Factor-Binding Protein-3 and Insulin Resistance: A Pilot Study”. Clinics 67, no. 3 (January 1, 2012): 283–287. Accessed May 14, 2024. https://www.revistas.usp.br/clinics/article/view/19668.